164 related articles for article (PubMed ID: 9021177)
1. SRR-SB3, a disulfide-containing macrolide that inhibits a late stage of the replicative cycle of human immunodeficiency virus.
Witvrouw M; Balzarini J; Pannecouque C; Jhaumeer-Laulloo S; Esté JA; Schols D; Cherepanov P; Schmit JC; Debyser Z; Vandamme AM; Desmyter J; Ramadas SR; de Clercq E
Antimicrob Agents Chemother; 1997 Feb; 41(2):262-8. PubMed ID: 9021177
[TBL] [Abstract][Full Text] [Related]
2. Anti-HIV activity and mechanism of action of macrocyclic diamide SRR-SB3.
Mahmood N; Jhaumeer-Lauloo S; Sampson J; Houghton PJ
J Pharm Pharmacol; 1998 Dec; 50(12):1339-42. PubMed ID: 10052846
[TBL] [Abstract][Full Text] [Related]
3. Polyanionic (i.e., polysulfonate) dendrimers can inhibit the replication of human immunodeficiency virus by interfering with both virus adsorption and later steps (reverse transcriptase/integrase) in the virus replicative cycle.
Witvrouw M; Fikkert V; Pluymers W; Matthews B; Mardel K; Schols D; Raff J; Debyser Z; De Clercq E; Holan G; Pannecouque C
Mol Pharmacol; 2000 Nov; 58(5):1100-8. PubMed ID: 11040059
[TBL] [Abstract][Full Text] [Related]
4. Pyrido [1,2a] indole derivatives identified as novel non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1.
Taylor DL; Ahmed PS; Chambers P; Tyms AS; Bedard J; Duchaine J; Falardeau G; Lavallée JF; Brown W; Rando RF; Bowlin T
Antivir Chem Chemother; 1999 Mar; 10(2):79-86. PubMed ID: 10335402
[TBL] [Abstract][Full Text] [Related]
5. Pronounced in vitro and in vivo antiretroviral activity of 5-substituted 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy] pyrimidines.
Balzarini J; Schols D; Van Laethem K; De Clercq E; Hocková D; Masojidkova M; Holý A
J Antimicrob Chemother; 2007 Jan; 59(1):80-6. PubMed ID: 17124193
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of human immunodeficiency virus type (HIV-1) replication by some diversely functionalized spirocyclopropyl derivatives.
Witvrouw M; Pannecouque C; De Clercq E; Fernández-Alvarez E; Marco JL
Arch Pharm (Weinheim); 1999 May; 332(5):163-6. PubMed ID: 10366901
[TBL] [Abstract][Full Text] [Related]
7. Unique anti-human immunodeficiency virus activities of the nonnucleoside reverse transcriptase inhibitors calanolide A, costatolide, and dihydrocostatolide.
Buckheit RW; White EL; Fliakas-Boltz V; Russell J; Stup TL; Kinjerski TL; Osterling MC; Weigand A; Bader JP
Antimicrob Agents Chemother; 1999 Aug; 43(8):1827-34. PubMed ID: 10428899
[TBL] [Abstract][Full Text] [Related]
8. Nonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication.
Romero DL; Busso M; Tan CK; Reusser F; Palmer JR; Poppe SM; Aristoff PA; Downey KM; So AG; Resnick L
Proc Natl Acad Sci U S A; 1991 Oct; 88(19):8806-10. PubMed ID: 1717988
[TBL] [Abstract][Full Text] [Related]
9. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis.
Witvrouw M; Pannecouque C; Switzer WM; Folks TM; De Clercq E; Heneine W
Antivir Ther; 2004 Feb; 9(1):57-65. PubMed ID: 15040537
[TBL] [Abstract][Full Text] [Related]
10. The naphthyridinone GSK364735 is a novel, potent human immunodeficiency virus type 1 integrase inhibitor and antiretroviral.
Garvey EP; Johns BA; Gartland MJ; Foster SA; Miller WH; Ferris RG; Hazen RJ; Underwood MR; Boros EE; Thompson JB; Weatherhead JG; Koble CS; Allen SH; Schaller LT; Sherrill RG; Yoshinaga T; Kobayashi M; Wakasa-Morimoto C; Miki S; Nakahara K; Noshi T; Sato A; Fujiwara T
Antimicrob Agents Chemother; 2008 Mar; 52(3):901-8. PubMed ID: 18160521
[TBL] [Abstract][Full Text] [Related]
11. Human immunodeficiency virus mutagenesis during antiviral therapy: impact of drug-resistant reverse transcriptase and nucleoside and nonnucleoside reverse transcriptase inhibitors on human immunodeficiency virus type 1 mutation frequencies.
Chen R; Yokoyama M; Sato H; Reilly C; Mansky LM
J Virol; 2005 Sep; 79(18):12045-57. PubMed ID: 16140780
[TBL] [Abstract][Full Text] [Related]
12. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
Taylor DL; Ahmed PS; Tyms AS; Wood LJ; Kelly LA; Chambers P; Clarke J; Bedard J; Bowlin TL; Rando RF
Antivir Chem Chemother; 2000 Jul; 11(4):291-301. PubMed ID: 10950391
[TBL] [Abstract][Full Text] [Related]
13. Biological and biochemical anti-HIV activity of the benzothiadiazine class of nonnucleoside reverse transcriptase inhibitors.
Buckheit RW; Fliakas-Boltz V; Decker WD; Roberson JL; Pyle CA; White EL; Bowdon BJ; McMahon JB; Boyd MR; Bader JP
Antiviral Res; 1994 Sep; 25(1):43-56. PubMed ID: 7529014
[TBL] [Abstract][Full Text] [Related]
14. S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1.
Fujiwara T; Sato A; el-Farrash M; Miki S; Abe K; Isaka Y; Kodama M; Wu Y; Chen LB; Harada H; Sugimoto H; Hatanaka M; Hinuma Y
Antimicrob Agents Chemother; 1998 Jun; 42(6):1340-5. PubMed ID: 9624472
[TBL] [Abstract][Full Text] [Related]
15. [Decrease of HIV-1 replicative capacity after serial passage in MT-4 cells under conditions of the combined antiretroviral therapy].
Selimova LM; Khanina TA; Galegov GA
Antibiot Khimioter; 2003; 48(6):7-10. PubMed ID: 14558412
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of human immunodeficiency virus replication by RD6-Y664, a novel benzylhydroxylamine derivative.
Okamoto M; Fujiwara M; Kodama E; Yamamoto O; Shigeta S; Mitsuya H; Konno K; Yokota T; Baba M
Antivir Chem Chemother; 1999 Mar; 10(2):71-7. PubMed ID: 10335401
[TBL] [Abstract][Full Text] [Related]
17. The compound 6-chloro-1,4-dihydro-4-oxo-1-(beta-D-ribofuranosyl) quinoline-3-carboxylic acid inhibits HIV-1 replication by targeting the enzyme reverse transcriptase.
Souza TM; Cirne-Santos CC; Rodrigues DQ; Abreu CM; Tanuri A; Ferreira VF; Marques IP; de Souza MC; Fontes CF; Frugulhetti IC; Bou-Habib DC
Curr HIV Res; 2008 May; 6(3):209-17. PubMed ID: 18473784
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of human immunodeficiency virus type 1 replication by combination of transcription inhibitor K-12 and other antiretroviral agents in acutely and chronically infected cells.
Okamoto M; Okamoto T; Baba M
Antimicrob Agents Chemother; 1999 Mar; 43(3):492-7. PubMed ID: 10049256
[TBL] [Abstract][Full Text] [Related]
19. Anti-human immunodeficiency virus type 1 (HIV-1) activity of 2'-fluoro-2',3'-dideoxyarabinosyladenine (F-ddA) used in combination with other mechanistically diverse inhibitors of HIV-1 replication.
Buckheit RW; Russell JD; Pallansch LA; Driscoll JS
Antivir Chem Chemother; 1999 May; 10(3):115-9. PubMed ID: 10431610
[TBL] [Abstract][Full Text] [Related]
20. Metabolism of 2',3'-dideoxy-2',3'-didehydro-beta-L(-)-5-fluorocytidine and its activity in combination with clinically approved anti-human immunodeficiency virus beta-D(+) nucleoside analogs in vitro.
Dutschman GE; Bridges EG; Liu SH; Gullen E; Guo X; Kukhanova M; Cheng YC
Antimicrob Agents Chemother; 1998 Jul; 42(7):1799-804. PubMed ID: 9661024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
